Abstract
Aim. To provide an overview of current knowledge on pharmacotherapy of premature ejaculation (PE). Materials and Methods. A comprehensive review of the literature was conducted using MEDLINE and analysis of crossreferences. The key points of methodology and pharmacology of various articles have been analysed and critically reviewed. Results. PE may have significant negative impact on quality of life. Various recommendations for drug treatment of PE have been found in the available literature, varying from anesthetic ointments to various antidepressants and phosphodiesterase inhibitors. Due to disturbing side effects, various drugs are not suitable for general use. On the other hand, topical anesthetics, clomipramine and some SSRIs have repeatedly been found safe and effective to delay ejaculation. Conclusions. Remarkable progress has been made in the treatment of PE. Further research into the neural, psychological and molecular mechanisms involved in PE will lead to the development of even safer, more effective and more convenient therapies for men with PE.
Keywords: Premature ejaculation, treatment, diagnosis
Current Drug Therapy
Title: Pharmacotherapy for Premature Ejaculation
Volume: 1 Issue: 1
Author(s): M. R. Safarinejad and S. Y. Hosseini
Affiliation:
Keywords: Premature ejaculation, treatment, diagnosis
Abstract: Aim. To provide an overview of current knowledge on pharmacotherapy of premature ejaculation (PE). Materials and Methods. A comprehensive review of the literature was conducted using MEDLINE and analysis of crossreferences. The key points of methodology and pharmacology of various articles have been analysed and critically reviewed. Results. PE may have significant negative impact on quality of life. Various recommendations for drug treatment of PE have been found in the available literature, varying from anesthetic ointments to various antidepressants and phosphodiesterase inhibitors. Due to disturbing side effects, various drugs are not suitable for general use. On the other hand, topical anesthetics, clomipramine and some SSRIs have repeatedly been found safe and effective to delay ejaculation. Conclusions. Remarkable progress has been made in the treatment of PE. Further research into the neural, psychological and molecular mechanisms involved in PE will lead to the development of even safer, more effective and more convenient therapies for men with PE.
Export Options
About this article
Cite this article as:
Safarinejad R. M. and Hosseini Y. S., Pharmacotherapy for Premature Ejaculation, Current Drug Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157488506775268434
DOI https://dx.doi.org/10.2174/157488506775268434 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurovascular Mechanisms of Hypertension in Pregnancy
Current Neurovascular Research Plant Sterols and Stanols in the Treatment of Dyslipidemia: New Insights into Targets and Mechanisms Related to Cardiovascular Risk
Current Pharmaceutical Design Does Parkinson’s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?
CNS & Neurological Disorders - Drug Targets Pharmacophore and 3D QSAR Study of TGFβ Inhibitors
Letters in Drug Design & Discovery Expression and Function of the Leukocyte Integrins in Medicine
Current Genomics Current Advancements in Aβ Luminescent Probes and Inhibitors of Aβ Aggregation
Current Alzheimer Research How Recent Patents Have Changed our Clinical Approach in Cardio-Thoracic Surgery
Recent Patents on Regenerative Medicine Therapeutic Interventions to Renin-Angiotensin-Aldosterone System, and Vascular Redox State
Recent Patents on Cardiovascular Drug Discovery Understanding Membrane Protein Drug Targets in Computational Perspective
Current Drug Targets Soluble RAGE-Modulating Drugs: State-of-the-Art and Future Perspectives for Targeting Vascular Inflammation
Current Vascular Pharmacology Drug Delivery Systems for the Treatment of Diabetes Mellitus: State of the Art
Current Pharmaceutical Design Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued) Vitamin D3, D2 and Arterial Wall Properties in Coronary Artery Disease
Current Pharmaceutical Design Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders:A Potential Noveltreatment?
Current Neuropharmacology Editorial [Hot Topic: Novel Peptides and Proteins in Diabetes Mellitus (Guest Editors: Po Sing Leung and Marc de Gasparo)]
Current Protein & Peptide Science The Antimitotic Potential of PARP Inhibitors, An Unexplored Therapeutic Alternative
Current Topics in Medicinal Chemistry Lifestyle Changes and Surgical Treatment for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry miR-27b-3p is Highly Expressed in Serum of Patients with Preeclampsia and has Clinical Significance
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical Review of COVID-19; Pathogenesis, Diagnosis, and Management
Current Pharmaceutical Design